Community Pharmacists' Knowledge Regarding Donepezil Averse Effects and Self-Care Recommendations for Insomnia for Persons with AD.
Study Design
- Çalışma Türü
- Cross-sectional
- Örneklem Büyüklüğü
- 862
- Müdahale
- Community Pharmacists' Knowledge Regarding Donepezil Averse Effects and Self-Care Recommendations for Insomnia for Persons with AD. None
- Karşılaştırıcı
- Placebo
- Etki Yönü
- Neutral
- Yanlılık Riski
- Moderate
Abstract
Alzheimer's disease (AD) impacts millions of individuals worldwide. Since no cure is currently available, acetylcholinesterase inhibitors are symptomatic therapy. This study assessed community pharmacists' knowledge regarding donepezil adverse effects (AEs) and self-care recommendations for insomnia management for persons with AD treated with rivastigmine. This is a cross-sectional, standardized telephone survey of community pharmacists (n = 862) in three study areas: West Virginia, North Dakota/South Dakota, and Southern Oregon/Northern California. Pharmacists' degree, sex, and pharmacists' AD-related knowledge were assessed. In-stock availability of donepezil and rivastigmine formulations was assessed. Analyses were performed using Stata 10.1. Only 31.4% pharmacists were able to name ≥2 donepezil AEs. Only four donepezil AEs were named by at least 13% of pharmacists: nausea (36.1%), dizziness (25.1%), diarrhea (15.0%), and vomiting (13.9%). All other AEs were named by fewer than 7% of respondents. Only 62.9% of pharmacists (n = 542) provided appropriate recommendations: melatonin (40.3%), referral to physician (22.0%), or sleep hygiene (0.6%). Over 12% of pharmacists (n = 107) provided inappropriate recommendations (anticholinergic agent or valerian root) and 21.5% of pharmacists were unable to provide any recommendation. We identified significant gaps in community pharmacists' knowledge regarding donepezil AEs and non-prescription insomnia recommendation needing significant improvement to ensure high-quality AD-related care.
Full Text
Tables
Table 4
| Recommendation | % | |
|---|---|---|
| 542 | 62.9% | |
| | 347 | 40.3% |
| | 190 | 22.0% |
| | 5 | 0.6% |
| 107 | 12.4% | |
| | 104 | 12.1% |
| | 3 | 0.4% |
| 185 | 21.5% | |
| 28 | 3.3% |
References
- 2017 Alzheimer’s Disease Facts and Figures
- Pathogenesis of Alzheimer's disease Clin. Interv. Aging, 2007
- Untitled Policy Brief: The Global Impact of Dementia 2013–2050, 2013
- Aricept (Donepezil Hydrochloride) Tablets Package Insert
- Razadyne (Galantamine Hydrobromide) Tablets Package Insert
- Exelon (Rivastigmine Tartrate) Capsules Package Insert
- Exelon (Rivastigmine Transdermal System) Patch Package Insert
- Namenda (Memantine HCl) Tablets for Oral Use, Package Insert
- Practice Parameter: Management of Dementia (an Evidence-Based Review). Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology, 2001
- Efficacy of cognitive enhancers for Alzheimer’s disease: Protocol for a systemic review and network meta-analysis Syst. Rev., 2012
- A Program Guide for Public Health: Partnering with Pharmacists in the Prevention and Control of Chronic Diseases
- Improving Patient and Health System Outcomes through Advanced Pharmacy Practice: A Report to the U.S. Surgeon General
- White paper on expanding the role of pharmacists in caring for individuals with Alzheimer’s disease: APhA Foundation Coordinating Council to Improve Collaboration in Supporting Patients with Alzheimer’s Disease J. Am. Pharm. Assoc., 2008
- United States Census Bureau
- The pharmacist’s role in supporting people living with dementia in the community Aust. Pharm., 2015
- Cognitive memory screening and referral program in community pharmacies in the United States Int. J. Clin. Pharm., 2014
- Pharmacists’ contributions to primary care in the United States collaborating to address unmet patient care needs: The emerging role for pharmacists to address the shortage of primary care providers Am. J. Pharm. Educ., 2010
- Community pharmacists’ knowledge of Alzheimer’s disease care in high- and low-income Chicago J. Am. Pharm. Assoc., 2017
- Knowledge and pharmacological management of Alzheimer’s disease by managing community pharmacists: A nationwide study Int. J. Clin. Pharm., 2016
- Community pharmacists and people with dementia: A cross-sectional survey exploring experiences, attitudes, and knowledge of pain and its management Int. J. Geriatr. Psychiatry, 2013
- Innovative Community Pharmacy Practice Models in North Carolina N. C. Med. J., 2017
- Provision of Clinical Preventive Services by Community Pharmacists Prev. Chronic Dis., 2016
- Adherence and Tolerability of Alzheimer’s Disease Medications: A Pragmatic Randomized Trial J. Am. Geriatr. Soc., 2017
- Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: A 2-year prospective, multicentre, cohort study CNS Drugs, 2010
- Adherence to medication in patients with dementia: Predictors and strategies for improvement Drugs Aging, 2008
- Discontinuation of donepezil for the treatment of Alzheimer’s disease in geriatric practice Int. Psychogeriatr., 2008
- Effectiveness of Pharmacists’ Comprehensive Assessment of Medication Profiles in Dementia Patients Yakugaku Zasshi, 2015
- Pilot study of dementia medication compliance conducted among pharmacists providing home visits which evaluates the degree of drug compliance, as defined by numerous attributes, between patients at home and patients in a medical facility Yakugaku Zasshi, 2012
- Pharmacist-based Donepezil Outpatient Consultation Service to improve medication persistence Patient Prefer Adherence, 2012
- Comedication and Treatment Length in Users of Acetylcholinesterase Inhibitors Demen Geriatr. Cogn. Dis. Extra, 2017
- American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults J. Am. Geriatr. Soc., 2015
- Disease-modifying drugs in Alzheimer’s disease Drug Des. Dev. Ther., 2013
- Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia CMAJ, 2008
- Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition Pharmacotherapy, 2005
- Acetylcholine: A neurotransmitter for learning and memory? Brain Res. Rev., 1995
- Review of Safety and Efficacy of Sleep Medicines in Older Adults Clin. Ther., 2016
- In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4 J. Pharm. Pharm. Sci., 2004
- Circadian Disruption Associated with Alzheimer's Disease Curr. Neurol. Neurosci. Rep., 2017
- Treatment of sleep disturbance in Alzheimer's dementia Int. J. Geriatr. Psychiatry, 2011
- Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer’s disease Sleep Med., 2007
- Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia J. Nippon. Med. Sch., 2003
- Pharmacotherapies for sleep disturbances in dementia Cochrane Database Syst. Rev., 2016
- Potentially inappropriate anticholinergic medication use in older adults with dementia J. Am. Pharm. Assoc., 2015
- Prevalence and predictors of anticholinergic agents in elderly outpatients with dementia Am. J. Geriatr. Pharmacother., 2011
- Over-the-counter medications containing diphenhydramine and doxylamine used by older adults to improve sleep Int. J. Clin. Pharm., 2017
Used In Evidence Reviews
Similar Papers
Journal of sleep research · 2017
European guideline for the diagnosis and treatment of insomnia.
Chronobiology international · 2012
Circadian typology: a comprehensive review.
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2017
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.
Movement disorders : official journal of the Movement Disorder Society · 2011
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.
Cell · 1981
Regulation of terminal differentiation of cultured human keratinocytes by vitamin A.
Journal of neuroendocrinology · 2003